Aprea Therapeutics (APRE) Other Non Operating Income (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Other Non Operating Income of $7711.0 for Q1 2026, down 94.96% year-over-year from $152923.0 in Q1 2025, and down 98.93% quarter-over-quarter from $720885.0 in Q4 2025.
Aprea Therapeutics (APRE) Other Non Operating Income (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Other Non Operating Income for 9 consecutive years, with $7711.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 94.96% year-over-year to $7711.0; the TTM figure through Mar 2026 stood at $871808.0 (up 10.09% YoY), while the FY2025 annual figure was $634267.0, down 53.4% from the prior year.
- Other Non Operating Income fell to $7711.0 in Q1 2026 per APRE's latest filing, from $720885.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.1 million in Q4 2023 and bottomed at -$33596.0 in Q4 2022.
- Historically, Other Non Operating Income has averaged $242792.8 across 5 years, with a median of $152923.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 146.78% — and 2023, when it surged 3509.69%.
- Aprea Therapeutics' Other Non Operating Income stood at -$33596.0 in 2022, then soared by 3509.69% to $1.1 million in 2023, then slumped by 71.08% to $331246.0 in 2024, then surged by 117.63% to $720885.0 in 2025, then sank by 98.93% to $7711.0 in 2026.
- Business Quant data shows APRE's Other Non Operating Income at $7711.0 in Q1 2026, $720885.0 in Q4 2025, and -$5691.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 440,876.00 |
| Mar 31, 2026 | 7,711.00 |
| Dec 31, 2025 | 720,885.00 |
| Sep 30, 2025 | -5,691.00 |
| Jun 30, 2025 | 148,903.00 |
| Mar 31, 2025 | 152,923.00 |
| Dec 31, 2024 | 331,246.00 |
| Sep 30, 2024 | 313,247.00 |
| Jun 30, 2024 | -5,502.00 |
| Mar 31, 2024 | 339,579.00 |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 318,335.00 |
| Jun 30, 2023 | 392,584.00 |
| Mar 31, 2023 | -13,797.00 |
| Dec 31, 2022 | -33,596.00 |
| Sep 30, 2022 | 24,353.00 |
| Jun 30, 2022 | 154,566.00 |
| Mar 31, 2022 | 136,211.00 |
| Dec 31, 2021 | 71,817.00 |
| Sep 30, 2021 | -21,907.00 |